Bryanna L. Norden

ORCID: 0000-0003-2084-473X

Immunology and MicrobiologyBiochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker”.

Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0313

N/A

1.7DataRank · unranked

85 citations

Connie Wu, Peter C. Fridy, Stephanie J. Zhang, Yasmeen Senussi, Justina C. Wolters +54 more

Sotorasib Is a Pan- RAS G12C Inhibitor Capable of Driving Clinical Response in NRAS G12C Cancers

Cancer Discovery(2024)10.1158/2159-8290.cd-23-1138

N/A

1.3DataRank · unranked

43 citations

Noritaka Tanaka, Ferran Fece de la Cruz, Kevin S. Kapner, Michael H. Rosenthal, Bryanna L. Norden +8 more

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors

Annals of Oncology(2025)10.1016/j.annonc.2025.01.020

N/A

0.601DataRank · unranked

54 citations

Ferran Fece de la Cruz, W. Marston Linehan, Christine M. Parseghian, Jonathan Kim, Hiroyuki Matsubara +19 more

TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2771

N/A

0.574DataRank · unranked

45 citations

Bogang Wu, Haley Barnes, Arielle J. Medford, Bryanna L. Norden, Annika Putur +16 more

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3135

N/A

0.546DataRank · unranked

37 citations

T. Khanh, Jeong Eun Kim, James M. Cleary, Aparna R. Parikh, Oladapo Yeku +26 more

The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3588

N/A

0DataRank · unranked

16 citations

Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L. Norden, Ryan B. Corcoran +11 more

Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0704

N/A

0DataRank · unranked

61 citations

Ferran Fece de la Cruz, Elizabeth E. Martin, Bryanna L. Norden, Nicholas Chevalier, Allison M. Kehlmann +26 more

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1317

N/A

0DataRank · unranked

80 citations

Haley Ellis, Giulia Siravegna, Alexa Michel, Bryanna L. Norden, Ferran Fece de la Cruz +7 more

MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-3284

N/A

0DataRank · unranked

3 citations

Hatice D. Saatcioglu, Haley Ellis, Elia Aguado-Fraile, Qin Xu, Hiroshi Kondo +20 more